Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lucigen Corporation and Research Corporation Technologies Announce Partnership

Published: Thursday, May 02, 2013
Last Updated: Thursday, May 02, 2013
Bookmark and Share
Partnership to commercialize and distribute the CleanColi™ Expression System, the first Escherichia coli (E. coli)-based recombinant system that lacks unwanted endotoxin.

Lucigen will produce and sell kits containing CleanColi™ competent cells and provide contract research services for the CleanColi™ Expression System. Lucigen simultaneously announces the release of a CleanColi™ competent cell line enabling the production of proteins virtually free of endotoxin contamination, thereby minimizing purification and allowing faster and more accurate screening of biological targets for drug discovery research. Under the partnership, RCT will be responsible for the CleanColi™ commercial licensing programs.

Drug discovery researchers are increasingly turning to biologics as the source for new therapeutics, utilizing the incredible diversity of proteins in order to find new treatments for disease. To synthesize and manipulate these proteins, researchers normally insert genes coding for the desired protein into mammalian, yeast, or bacterial cells. The common bacteria E. coli is a widely used system for expression of recombinant proteins, but this method has the disadvantage that, without time-consuming and expensive cleanup, it produces contaminating endotoxin that kills human cells. Failure to remove endotoxin from the final product can result in false or misleading results, potentially causing a researcher to improperly reject a promising drug candidate.

Lucigen and RCT have developed the CleanColi™ competent cell strain for protein expression. This new strain has a genetically modified lipopolysaccharide (LPS) that does not cause an endotoxic response in human cells. By producing proteins without contaminating endotoxin, researchers can increase productivity by reducing the time, cost, and loss of product associated with endotoxin removal. More important, cell-based assays can be performed without concern that LPS (endotoxin) contamination could be masking promising results. Researchers can accelerate drug discovery research and ensure the most accurate results possible. Additional cell lines for plasmid production and phage display are also planned for release, creating a complete system for scientists to study a large variety of biologic compounds for therapeutic applications.

“E. coli is commonly used for research scale protein expression but its ease of use has been limited by unwanted endotoxin contamination. These days are hopefully over. RCT and their collaborators have developed technology allowing for the creation of the first viable E.coli strains lacking endotoxin in the membrane. The CleanColi™ cell lines will accelerate how researchers screen novel compounds for drug discovery. By eliminating the source of endotoxin, scientists can increase the number of compounds screened and more accurately pinpoint candidates for further testing. We are proud to work with RCT to introduce this truly novel system to the world,” states David Mead, Ph.D., Lucigen founder and CEO.

“Lucigen is the ideal partner to launch the CleanColi™ Expression System. They have established themselves as the clear market leader for high efficiency competent cells. We are looking forward to working with them and future licensees of the CleanColi™ Expression System to bring this valuable tool to commercial research and recombinant protein production,” said Chad Souvignier, Ph.D., Managing Director at RCT.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos